Lucius LuciCeno Cenobamate 50mg

Product Information

• Product name: LuciCeno Cenobamate 50mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Cenobamate
• Current strength: 50mg
• SKU: LU-ITEM-143
• Site category: epilepsy, other cancer

Product Summary

LuciCeno Cenobamate 50mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Cenobamate is the active ingredient used for this product page. Public prescribing information for Cenobamate was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABA A ) ion channel.

Reference Indications

Cenobamate is indicated for the treatment of partial-onset seizures in adult patients. Cenobamate is indicated for the treatment of partial-onset seizures in adult patients.

Reference Dosage and Administration

Recommended dosage is 200 mg once daily. taken whole or the tablets can be crushed.

With this 50mg product, that corresponds to 4 x 50mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multi-Organ Hypersensitivity: Discontinue if no alternate etiology. QT Shortening: Use caution when administering Cenobamate with other drugs that shorten the QT interval Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and ideation. Liver Injury: Clinically significant liver injury has occurred. Obtain serum transaminases (ALT and AST) and total bilirubin before initiating Cenobamate, and during treatment if clinically indicated. Discontinue Cenobamate in patients with evidence of liver injury in the absence of an alternative etiology. Concomitant use with other CNS depressants or alcohol may have additive effects. Withdrawal of Antiepileptic Drugs: Cenobamate should be gradually withdrawn to minimize the potential of increased seizure frequency.

Common Adverse Reactions and Monitoring

A total of 658 patients (442 patients treated with Cenobamate and 216 patients treated with placebo) constituted the safety population in the pooled analysis of placebo-controlled studies in patients with partial-onset seizures (Studies 1 and 2) . The discontinuation rates because of adverse events were 11%, 9%, and 21% for patients randomized to receive Cenobamate at doses of 100 mg/day, 200 mg/day, and 400 mg/day, respectively, compared to 4% in patients randomized to receive placebo. The maximum ALT elevation was 7.6 times ULN in patients treated with 400 mg Cenobamate.

Drug Interactions and Special Populations

Phenytoin: Gradually decrease phenytoin dosage by up to 50%. Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with Cenobamate. Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with Cenobamate. CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with Cenobamate. CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with Cenobamate. Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with Cenobamate. Women should use additional or alternative non-hormonal birth control. carbamazepine ↓ plasma concentrations phenytoin ↑ plasma concentrations Because of a potential 2-fold increase in phenytoin levels, gradually decrease phenytoin dosage by up to 50% as Cenobamate is being titrated.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Xcopri public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.